Carvedilol down- regulates matrix metalloproteinase- 9 production in human leukemic MOLT-4 T cells

Fatemeh Hajighasemi | Amirhossein Gaeini

---

URL :   http://research.shahed.ac.ir/WSR/WebPages/Report/PaperView.aspx?PaperID=158897
Date :  2021/06/30
Publish in :    World Immune Regulation Meeting XV 2021

Link :  http://WIRM
Keywords :Carvedilol; MOLT-4; MMP-9

Abstract :

---

Background: Matrix metalloproteinases (MMPs), a big cluster of enzymes destroys the extracellular matrix, are complicated in numerous inflammatory- based diseases. MMP-9 plays a fundamental role in inflammation. Carvedilol is a nonspecific β- blocker has been applied for controlling of hypertension and congestive heart failure. Moreover the anti-inflammatory properties of carvedilol have been revealed. In present study the effect of carvedilol on MMP-9 production in leukemic MOLT-4 cells has been studied in vitro. Materials and methods: Human leukemic MOLT-4 cells were cultured in RPMI complete medium. Subsequently the cells at logarithmic growth stage were inspired with optimal dose of PMA and treated with different concentrations of carvedilol (0.001-0.1 mg/ml) for 24 hours. Levels of MMP-9 in culture supernates were defined by an enzyme-linked immunosorbent assay kit (R&D system). Results: Carvedilol significantly declined MMP-9 creation by leukemic MOLT-4 cells dose dependently in comparison with untreated control cells. Conclusion: Our results showed that carvedilol down- regulates production of MMP-9 in human leukemic MOLT-4 cells. As MMP-9 has an important role in inflammation, the anti-inflammatory properties of carvedilol may be partly owing to its inhibitory effects on MMP-9 production. Thus it appears that carvedilol might be valuable for treatment of inflammatory diseases such as asthma in which MMP-9 is highly expressed.

http://WIRM